553631-79-1

Basic information

• Product Name: N-methyl-N-(4-piperazin-1-ylphenyl)-acetamide
• Synonyms: N-methyl-N-(4-piperazin-1-ylphenyl)-acetamide
• CAS NO: 553631-79-1
• Molecular Weight: 233.313
• Mol File: 553631-79-1.mol

Chemical Properties

• CAS DataBase Reference: N-methyl-N-(4-piperazin-1-ylphenyl)-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-N-(4-piperazin-1-ylphenyl)-acetamide(553631-79-1)
• EPA Substance Registry System: N-methyl-N-(4-piperazin-1-ylphenyl)-acetamide(553631-79-1)

Safety Data

• Hazardous Substances Data: 553631-79-1(Hazardous Substances Data)

Upstream product

• 553631-77-9 4-[4-(acetylmethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 110-85-0 piperazine 
• 50438-47-6 N-(4-bromo-phenyl)-N-methylacetamide 
• 198627-94-0 4-(4-acetylaminophenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 6269-89-2 1-(4-Nitrophenyl)piperazine 
• 182618-86-6 tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate 
• 170911-92-9 4-(4-aminophenyl)-1-t-butyloxycarbonylpiperazine 

Relevant articles and documents

ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS

The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use

The subject invention provides compounds having the structure: 1 wherein,R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra;R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, orR1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH;R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb;R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl;R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12;wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring;R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl;R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, orR8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring;R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring;R11, N and R12 together form a 4-8 membered heterocyclic ring;Ra and Rb are each independently hydrogen or alkyl;m is 0, 1, 2 or 3; andk is 1, 2 or 3,or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.